Pfizer Lyrica Undergoing Controlled Substance Scheduling At DEA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears pregabalin for management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. The Neurontin follow-on compound remains "approvable" for the adjunctive treatment of partial seizures in adults with epilepsy.